Experienced in Hodgkin Lymphoma

Dr. Mariko Sato

Pediatric Hematology Oncology

Providence

1201 West La Veta Avenue,

Orange, CA

Clinical Trials:Currently Recruiting for 9 Trials

Accepting New Patients

Experienced in Hodgkin Lymphoma

Providence

1201 West La Veta Avenue,

Orange, CA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mariko Sato is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Sato is rated as an Experienced provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Glioma, Medulloblastoma, Hepatoblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration. Dr. Sato is currently accepting new patients.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 66 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Hodgkin Lymphoma.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in UT

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana

HMO
INDEMNITY
POS
PPO

Inland Empire Health Plan

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE

Medicaid

OTHER MEDICAID
STATE MEDICAID

Sanford Health

UnitedHealthcare

View 4 Less Insurance Carriers -

Locations

1201 West La Veta Avenue, Orange, CA 92868

Call: 714-509-8636

Additional Areas of Focus

Dr. Sato has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

66 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Other, Drug

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone

Study Phase: Phase 3

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Radiation, Drug, Procedure

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine

Study Phase: Phase 2

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate

Study Phase: Phase 3

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine

Study Phase: Phase 3

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine

Study Phase: Phase 2

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Enrollment Status: Recruiting

Publish Date: September 10, 2025

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 2

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Enrollment Status: Recruiting

Publish Date: August 12, 2025

Intervention Type: Other

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Enrollment Status: Active_not_recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Biological

Study Drugs: Axitinib, Nivolumab

Study Phase: Phase 2

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Radiation

Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Other

Study Drugs: Cabozantinib, Cabozantinib-S-Malate

Study Phase: Phase 2

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Radiation, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Other, Drug

Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib

Study Phase: Phase 3

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Selumetinib, Vinblastine

Study Phase: Phase 3

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine

Study Phase: Phase 3

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: July 16, 2025

Intervention Type: Procedure, Drug

Study Drug: Trametinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Enrollment Status: Completed

Publish Date: April 23, 2025

Intervention Type: Other, Drug

Study Drug: Carvedilol

Study Phase: Phase 2

A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: April 18, 2025

Intervention Type: Other, Device

Study Phase: Phase 3

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: April 09, 2025

Intervention Type: Drug, Biological

Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide

Study Phase: Phase 2

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: April 01, 2025

Intervention Type: Other, Drug

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Renal Tumors Classification, Biology, and Banking Study

Enrollment Status: Active_not_recruiting

Publish Date: March 25, 2025

Intervention Type: Other

Key Adverse Events After Childhood Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 07, 2025

Intervention Type: Other

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

Enrollment Status: Completed

Publish Date: February 27, 2025

Intervention Type: Procedure, Drug

Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

View 41 Less Clinical Trials

19 Total Publications

Unusual Magnetic Resonance Imaging (MRI) Features of Neonatal Facial Nerve Palsy.

Journal: Journal of child neurology

Published: August 08, 2025

View All 19 Publications

Similar Doctors

Distinguished in Hodgkin Lymphoma

Dr. Saro H. Armenian

Pediatric Hematology Oncology

Distinguished in Hodgkin Lymphoma

Dr. Saro H. Armenian

Pediatric Hematology Oncology

1500 Duarte Rd,

Duarte, CA

(24.8 miles away)

626-359-8111

Languages Spoken:

English

See accepted insurances

Saro Armenian is a Pediatric Hematologist Oncology provider in Duarte, California. Dr. Armenian is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Primary Carnitine Deficiency, Hodgkin Lymphoma, Chronic Graft Versus Host Disease (cGvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Advanced in Hodgkin Lymphoma

Dr. Carol H. Lin

Pediatric Hematology Oncology

Advanced in Hodgkin Lymphoma

Dr. Carol H. Lin

Pediatric Hematology Oncology

1201 West La Veta Avenue,

Orange, CA

(0.1 miles away)

714-509-8636

Languages Spoken:

English

See accepted insurances

Carol Lin is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Lin is rated as an Advanced provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Osteosarcoma, Virus Associated Hemophagocytic Syndrome, and Hemophagocytic Lymphohistiocytosis.

Experienced in Hodgkin Lymphoma

Dr. Jamie N. Frediani

Pediatric Hematology Oncology

Experienced in Hodgkin Lymphoma

Dr. Jamie N. Frediani

Pediatric Hematology Oncology

1201 West La Veta Avenue,

Orange, CA

(0.1 miles away)

888-770-2462

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Jamie Frediani is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Frediani is rated as an Advanced provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Febrile Neutropenia, Hepatoblastoma, and Leukemia. Dr. Frediani is currently accepting new patients.

VIEW MORE HODGKIN LYMPHOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sato's expertise for a condition

ConditionClose